Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AMAG Pharmaceuticals, Inc.
This is a double-blind, placebo controlled, crossover design study of the safety of ferumoxytol compared to placebo. Patients are randomized to receive either one 510 mg dose of ferumoxytol or the equivalent volume of normal saline followed by the other test article given one week later.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female patients \> 18 years.
Have chronic kidney disease per K/DOQI guidelines.
Baseline hemoglobin of \> 9.0 and \< 12.5 g/dl
You may not be if
Women who are pregnant or lactating.
Received another investigational drug or device within 30 days.
Recent parenteral or oral iron therapy.
Patients that have other causes of anemia.
Major surgery within 30 days or anticipated or planned surgery during the study.
Patients with active infections.
Recent blood transfusions.
Patients with known allergies to iron products.
Clareo Health | A Crossover Safety Study of Ferumoxytol Versus Placebo
